- Glycopyrrolate
-
-
2026-02-17
- CAS:596-51-0
- Min. Order:
- Purity: 0.99
- Supply Ability:
- Glycopyrrolate Bromide
-
- $200.00 / 1g
-
2026-02-13
- CAS:596-51-0
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 200kg per month
- Glycopyrrolate
-
- $0.00 / 1g
-
2026-02-13
- CAS:596-51-0
- Min. Order: 1g
- Purity: 99%min
- Supply Ability: 100g
Related articles - Side effects of Glycopyrrolate
- Glycopyrronium bromide is a quaternary amine with similar anticholinergic actions to atropine but without central effects beca....
- Feb 18，2022
|
| | Glycopyrrolate Basic information |
| | Glycopyrrolate Chemical Properties |
| Melting point | 192-195°C | | density | 1.3222 (rough estimate) | | refractive index | 1.6200 (estimate) | | storage temp. | 2-8°C | | solubility | H2O: ≥24mg/mL | | form | powder | | color | white to tan | | Water Solubility | H2O: ≥24mg/mL | | Merck | 14,4501 | | Stability: | Hygroscopic | | InChI | InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1 | | InChIKey | VPNYRYCIDCJBOM-UHFFFAOYSA-M | | SMILES | C(O)(C(=O)OC1CC[N+](C)(C)C1)(C1=CC=CC=C1)C1CCCC1.[Br-] | | CAS DataBase Reference | 596-51-0(CAS DataBase Reference) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26 | | WGK Germany | 3 | | RTECS | UY4337630 | | HS Code | 29339900 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral
Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 | | Toxicity | LD50 (72 hr.) in female mice, female rats (mg/kg): 107, 196 i.p.; in male rats (mg/kg): 1150 orally (Franko) |
| | Glycopyrrolate Usage And Synthesis |
| Description | Glycopyrrolate is an antagonist of muscarinic acetylcholine receptors (mAChRs; Kis = 0.42, 1.77, 0.52, 0.78, and 1.29 nM for the M1-M5 receptors, respectively). It induces relaxation of precontracted isolated human bronchi when used at concentrations of 0.01, 0.1, or 1 μM. Glycopyrrolate reduces post-prandial gastric antral motility in dogs when administered at a dose of 0.01 mg/kg. It inhibits salivation in a rat model of sialorrhea induced by pilocarpine with an ED50 value of 0.74 μg/kg. Formulations containing glycopyrrolate have been used in the treatment of sialorrhea, peptic ulcers, and chronic obstructive pulmonary disease (COPD). | | Chemical Properties | White Solid | | Originator | Robinul,Robins,US,1961 | | Uses | Inhaled glycopyrrolate of is used to treat air flow blockage and prevent worsening of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. COPD is a long-term lung disease that causes bronchospasm (difficulty with breathing). | | Uses | Glycopyrrolate inhibits secretion of digestive juices and restores normal stomach function.
It is used for treating stomach ulcers, inflamed intestine, and also as a pre-operational drug
for inhibiting excess stomach secretion. | | Uses | sunscreen | | Uses | For use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and free acidity of gastric secretions and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubat | | Uses | A synthetic, quaternary ammonium anticholinergic. Antispasmodic; preanesthetic medicant. | | Definition | ChEBI: A quaternary ammonium salt composed of 3-{[cyclopentyl(hydroxy)phenylacetyl]oxy}-1,1-dimethylpyrrolidin-1-ium and bromide ions in a 1:1 ratio. | | Manufacturing Process | A mixture of 42.5 grams (0.17 mol) of methyl α-cyclopentyl mandelate and 18
grams (0.175 mol) of 1-methyl-3-pyrrolidinol in 500 ml of heptane was
refluxed under a Dean and Stark moisture trap, with the addition of four 0.1
gram pieces of sodium at 1-hour intervals. After 5 hours' refluxing the
solution was concentrated to one-half volume, and extracted with cold 3N HCl.
The acid extract was made alkaline with aqueous sodium hydroxide and
extracted with ether which was washed, dried over sodium sulfate, filtered
and concentrated. The residue was fractionated at reduced pressure. Yield 33
grams (64%); BP 151° to 154°C/0.2 mm, nD23= 1.5265.
The hydrochloride salt was precipitated as an oil from an ethereal solution of
the base with ethereal hydrogen chloride. It was crystallized from butanone;
MP 170° to 171.5°C.
The methyl bromide quaternary was prepared by saturating a solution of the
base in dry ethyl acetate with methyl bromide. After standing for 9 days the resulting crystalline solid was filtered and recrystallized from butanone and
from ethyl acetate; MP 193° to 194.5°C. | | Brand name | Robinul (Baxter Healthcare); Robinul (Sciele). | | Therapeutic Function | Spasmolytic | | General Description | Glycopyrrolate, 3-hydroxy-1,1-dimethylpyrrolidinium bromide -cyclopentylmandelate(Robinul), occurs as a white, crystalline powder that is solublein water or alcohol but practically insoluble in chloroformor ether.
Glycopyrrolate is a typical anticholinergic and possesses,at adequate dosage levels, the atropine-like effectscharacteristic of this class of drugs. It has a spasmolyticeffect on the musculature of the GI tract as well as the genitourinarytract. It diminishes gastric and pancreatic secretionsand the quantity of perspiration and saliva. Its sideeffects are also typically atropine-like (i.e., dryness of themouth, urinary retention, blurred vision, constipation).Glycopyrrolate is a more potent antagonist on M1 than onM2 and M3 receptors. The low affinity of M2 receptorsmay, in part, explain the low incidence of tachycardiaduring use of this drug as an antispasmodic.77 Because ofits quaternary ammonium character, glycopyrrolate rarelycauses CNS disturbances, although in sufficiently highdosage, it can bring about ganglionic and myoneural junctionblock. | | Biochem/physiol Actions | Glycopyrrolate is long-acting muscarinic antagonist (LAMA). It is kinetically selective muscarinic M3 receptor antagonist. | | Mechanism of action | Glycopyrrolate exhibits onset of action within 1 minute when given intravenously and an elimination half-life of approximately 50 minutes. Glycopyrrolate undergoes urinary excretion and elimination. | | Clinical Use | Glycopyrrolate is used as an adjunct in the management of pepticulcer and other GI ailments associated with hyperacidity,hypermotility, and spasm. In common with other anticholinergics,its use does not preclude dietary restrictions or use ofantacids and sedatives if these are indicated. | | Side effects | - dry mouth
- blurred vision
- vision problems
- loss of taste
- headache
- nervousness
- confusion
- drowsiness
| | Safety Profile | Poison by intravenous
and intraperitoneal routes. Moderately toxic
by ingestion and subcutaneous routes.
Experimental reproductive effects. When
heated to decomposition it emits very toxic
fumes of NOx and Br-. See also BROMIDES. | | Synthesis | Glycopyrrolate, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide (14.1.22), is synthesized from the methyl ester of |á-cyclopentylmandelic acid (14.1.20) by transesterification using 3-hydroxy-1-methylpyrrolidine as an
alcohol component, which forms the ester (14.1.21), which is further transformed into a
quaternary salt upon reaction with methylbromide, giving glycopyrrolate (14.1.22). The
starting methyl ester of |á-cyclopentylmandelic acid (14.1.20) is synthesized by reacting
cyclopentylmagnesiumbromide with the methyl ester of phenylglyoxylic acid [17,18]. 
| | Veterinary Drugs and Treatments | Glycopyrrolate injection is approved for use in dogs and cats. The
FDA approved
indication for these species is as a preanesthetic anticholinergic
agent. The drug is also used to treat sinus bradycardia,
sinoatrial arrest, and incomplete AV block, where anticholinergic
therapy may be beneficial. When cholinergic agents such as neostigmine
or pyridostigmine are used to reverse neuromuscular
blockade
due to non-depolarizing muscle relaxants, glycopyrrolate may
be administered simultaneously
to prevent the peripheral muscarinic
effects of the cholinergic agent. | | References | [1] AMADEU GAVALDà. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide[J]. Pulmonary pharmacology & therapeutics, 2014, 28 2: Pages 114-121. DOI: 10.1016/j.pupt.2014.05.005
[2] PAOLA ROGLIANI . Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi[J]. European journal of pharmacology, 2015, 761: Pages 383-390. DOI: 10.1016/j.ejphar.2015.04.042
[3] D. M. BURGER. Effect of Anticholinergics (Atropine, Glycopyrrolate) and Prokinetics (Metoclopramide, Cisapride) on Gastric Motility in Beagles and Labrador Retrievers[J]. Transboundary and Emerging Diseases, 2006, 53 2: 97-107. DOI: 10.1111/j.1439-0442.2006.00787.x |
| | Glycopyrrolate Preparation Products And Raw materials |
|